CD226 and acute myeloid leukemia: Wang et al. [15] also described the expansion in AML patients of a CD8+T cell subset expressing PD-1 and TIGIT and negative for DNAM-1 that was associated with poor prognosis such as failure to achieve remission after induction therapy or the presence of the FLT3-ITD mutation.